Advances in the polymeric delivery of nucleic acid vaccines
- PMID: 35673570
- PMCID: PMC9169366
- DOI: 10.7150/thno.70853
Advances in the polymeric delivery of nucleic acid vaccines
Abstract
Nucleic acid vaccines, especially messenger RNA (mRNA) vaccines, display unique benefits in the current COVID-19 pandemic. The application of polymeric materials as delivery carriers has greatly promoted nucleic acid vaccine as a promising prophylactic and therapeutic strategy. The inherent properties of polymeric materials render nucleic acid vaccines with excellent in vivo stability, enhanced biosafety, specific cellular uptake, endolysosomal escape, and promoted antigen expression. Although polymeric delivery of nucleic acid vaccines has progressed significantly in the past decades, clinical translation of polymer-gene vaccine systems still faces insurmountable challenges. This review summarizes the diverse polymers and their characterizations and representative formulations for nucleic acid vaccine delivery. We also discussed existing problems, coping strategies, and prospect relevant to applications of nucleic acid vaccines and polymeric carriers. This review highlights the rational design and development of polymeric vaccine delivery systems towards meeting the goals of defending serious or emerging diseases.
Keywords: cellular immunity; gene delivery; humoral immunity; nucleic acid vaccine; polymer.
© The author(s).
Conflict of interest statement
Competing Interests: The authors have declared that no competing interest exists.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9169366/bin/thnov12p4081g001.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9169366/bin/thnov12p4081g002.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9169366/bin/thnov12p4081g003.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9169366/bin/thnov12p4081g004.gif)
![Figure 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9169366/bin/thnov12p4081g005.gif)
![Figure 6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9169366/bin/thnov12p4081g006.gif)
![Figure 7](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9169366/bin/thnov12p4081g007.gif)
![Figure 8](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9169366/bin/thnov12p4081g008.gif)
![Figure 9](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9169366/bin/thnov12p4081g009.gif)
![Figure 10](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9169366/bin/thnov12p4081g010.gif)
![Figure 11](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9169366/bin/thnov12p4081g011.gif)
![Figure 12](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9169366/bin/thnov12p4081g012.gif)
Similar articles
-
Polymeric Delivery of Therapeutic Nucleic Acids.Chem Rev. 2021 Sep 22;121(18):11527-11652. doi: 10.1021/acs.chemrev.0c00997. Epub 2021 May 3. Chem Rev. 2021. PMID: 33939409
-
Dendrimer-Mediated Delivery of DNA and RNA Vaccines.Pharmaceutics. 2023 Mar 30;15(4):1106. doi: 10.3390/pharmaceutics15041106. Pharmaceutics. 2023. PMID: 37111593 Free PMC article. Review.
-
Polymeric nanoparticle vaccines to combat emerging and pandemic threats.Biomaterials. 2021 Jan;268:120597. doi: 10.1016/j.biomaterials.2020.120597. Epub 2020 Dec 10. Biomaterials. 2021. PMID: 33360074 Free PMC article. Review.
-
A Critical Assessment of COVID-19 Genomic Vaccines.Curr Top Med Chem. 2023;23(27):2552-2589. doi: 10.2174/1568026623666230825094341. Curr Top Med Chem. 2023. PMID: 37622697 Review.
-
Next-Generation Vaccines: Nanoparticle-Mediated DNA and mRNA Delivery.Adv Healthc Mater. 2021 Apr;10(8):e2001812. doi: 10.1002/adhm.202001812. Epub 2021 Jan 18. Adv Healthc Mater. 2021. PMID: 33458958 Free PMC article. Review.
Cited by
-
Immune Specific and Tumor-Dependent mRNA Vaccines for Cancer Immunotherapy: Reprogramming Clinical Translation into Tumor Editing Therapy.Pharmaceutics. 2024 Mar 25;16(4):455. doi: 10.3390/pharmaceutics16040455. Pharmaceutics. 2024. PMID: 38675116 Free PMC article. Review.
-
Advanced nano-based strategies for mRNA tumor vaccine.Acta Pharm Sin B. 2024 Jan;14(1):170-189. doi: 10.1016/j.apsb.2023.07.025. Epub 2023 Jul 29. Acta Pharm Sin B. 2024. PMID: 38239240 Free PMC article. Review.
-
Transcriptional Targeting of Dendritic Cells Using an Optimized Human Fascin1 Gene Promoter.Int J Mol Sci. 2023 Nov 29;24(23):16938. doi: 10.3390/ijms242316938. Int J Mol Sci. 2023. PMID: 38069260 Free PMC article.
-
Oral mucosa immunity: ultimate strategy to stop spreading of pandemic viruses.Front Immunol. 2023 Oct 19;14:1220610. doi: 10.3389/fimmu.2023.1220610. eCollection 2023. Front Immunol. 2023. PMID: 37928529 Free PMC article. Review.
-
mRNA vaccines and their delivery strategies: A journey from infectious diseases to cancer.Mol Ther. 2024 Jan 3;32(1):13-31. doi: 10.1016/j.ymthe.2023.10.024. Epub 2023 Nov 3. Mol Ther. 2024. PMID: 37919901 Review.
References
-
- Valencic E, Smid A, Jakopin Z, Tommasini A, Mlinaric-Rascan I. Repositioning drugs for rare immune diseases: Hopes and challenges for a precision medicine. Curr Med Chem. 2018;25:2764–82. - PubMed
-
- Whitworth HS, Gallagher KE, Howard N, Mounier-Jack S, Mbwanji G, Kreimer AR. et al. Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to no vaccination or standard three and two-dose vaccination regimens: A systematic review of evidence from clinical trials. Vaccine. 2020;38:1302–14. - PubMed
-
- Minor PD. Live attenuated vaccines: Historical successes and current challenges. Virology. 2015;479-480:379–92. - PubMed
-
- Excoffon K. The coxsackievirus and adenovirus receptor: Virological and biological beauty. FEBS Lett. 2020;594:1828–37. - PubMed
-
- Kulkarni JA, Witzigmann D, Thomson SB, Chen S, Meel R. The current landscape of nucleic acid therapeutics. Nat Nanotechnol. 2021;16:630–43. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous